The latest market report published by Acute Market Reports, Inc. “Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Docusate Sodium, Others), By Prescription Type (Prescribed, Over The Counter) – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global opioid induced constipation drugs market was valued at US$ 2,430.6 Mn in 2017, and is expected to reach US$ 3,770.4 Mn by 2026 expanding at a CAGR of 4.92% from 2018 to 2026.
Browse the full report at “Opioid Induced Constipation (OIC) Drugs Market”
Market Insights
In the present scenario, drugs such as osmotic laxatives and stimulant cathartics which are prescribed by physicians during the initial treatment of opioid induced constipation are leading the drug type segment. Naloxegol will register significant growth owing to its enhanced drug safety and tolerability in comparison to other mu-receptor antagonists prescribed for opioid induced constipation.
Prescription drugs are currently dominating the global market due to increasing number of patients not gaining relief from opioid induced constipation from over the counter laxatives and stimulant cathartics. Over the counter products show therapeutic effect only in patients taking opioid analgesics for 3-4 weeks.
Increasing number of patients suffering with non-cancer pain disorders such as rheumatoid arthritis and osteoarthritis are prescribed opioid analgesics which causes constipation will drive the OIC drugs market. Homecare settings are widely using drugs to treat opioid induced constipation for patients seeking palliative care. Asia Pacific will showcase rampant growth owing to huge population base suffering with chronic pain related to occupational hazards and poor regulations results in large adolescent population engaged in opioids misuse.
Manufacturers are constantly striving to provide drugs to treat OIC with least side effects. Recently naldemedine (Symproic) received USFDA approval for the treatment of chronic constipation induced by opioids in adults. Shionogi, Inc. the developer of the drug molecule has also registered a petition with the FDA for the removal of the controlled substance classification. Naldemedine will register excellent growth owing to enhanced drug safety and efficacy and probability to be sold as over the counter product. EA Pharma Co. Ltd has applied a JNDA for elobixibat in Japan for the treatment of chronic constipation; which will further drive the opioid induced constipation drugs market during the forecast period from 2018 to 2026.
The key players pioneering in the opioid induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd., Sucampo Pharmaceuticals, Inc., and Synergy Pharmaceuticals, Inc.
Key Market Movements:
By Drug Type
By Prescription Type
By Geography Segment
About Us
Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-855-455-8662
E-mail: sales@acutemarketreports.com
In today's fast-paced world, the concept of a home office has transcended traditional boundaries, paving…
Samsung is reportedly taking a new approach to its flagship lineup with the Galaxy S25…
DJI, a global leader in drone technology, has announced the launch of its latest innovation,…
In a groundbreaking collaboration, OpenAI and longevity-focused startup Retro Biosciences have developed a new AI…
Surge in Global Demand Powers Growth in Alternative Fuel Vehicles Market, CAGR to Hit 9.8%…
The spearmint oil market is expected to grow at a CAGR of 5.0% during the…